Cellares vs Degron Therapeutics
Cellares vs Degron Therapeutics, compared side by side on 14 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Cellares is on 54/100 and Degron Therapeutics on 62/100.
Where each one leads
Cellares
- agent readiness: 42/100 against 27/100
- domain rating: 43/100 against 24/100
- funding raised: $327M against $40.0M
Degron Therapeutics
- our overall score: 62/100 against 54/100
At a glance
| Measure | Cellares | Degron Therapeutics |
|---|---|---|
| What it is | The first Integrated Development and Manufacturing Organization (IDMO) for cell therapies. | Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines. |
| Category | Biotechnology, Pharmaceuticals, Healthcare, Life Sciences | Biotechnology, Pharmaceuticals, Drug Discovery, Healthcare |
| Sells toBusiness model | B2B | B2B |
| Offering | Services | Platform |
| Founded | 2019 | 2020 |
| Headquarters | South San Francisco, USA | San Diego, USA |
| Status | Active | Active |
Size, funding and growth
| Measure | Cellares | Degron Therapeutics |
|---|---|---|
| Employees | Not published | 24 |
| Total funding | $327M | $40.0M |
| Latest round | Funding Round | Series A Extension |
| Valuation | $1.1B | $1.1B |
| LinkedIn followers | Not published | 1,380 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Cellares | Degron Therapeutics |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 54/100 | 62/100 |
| Traction | 40/100 | Not published |
| Team | Not published | 24/100 |
| Search visibility | 15/100 | 57/100 |
| Quality | 78/100 | Not published |
| Agent readinessHow well an AI agent can read and act on the site | D (42/100) | F (27/100) |
| Domain ratingLink authority, 0-100 | 43/100 | 24/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Cellares | Degron Therapeutics |
|---|---|---|
| Hosting | Not detected | Self Managed |
| CDN | Cloudflare | Not detected |
| CMS | WordPress | Not detected |
| Frameworks | Jquery | Not detected |
| Analytics | Google Analytics 4 | Not detected |
| Support stack | HubSpot | Not detected |
What users say
| Measure | Cellares | Degron Therapeutics |
|---|---|---|
| Reddit sentimentThreads we track | 2 positive, 0 negative across 4 threads | Not published |
“Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel.”r/CABAinvest
Cellares vs Degron Therapeutics: common questions
Which is better, Cellares or Degron Therapeutics?
On our 0-100 score Degron Therapeutics rates higher (62/100 against 54/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 14 data points above: read the rows that match what you are buying for.
How do Cellares and Degron Therapeutics compare on the numbers?
Cellares leads on agent readiness (42/100 against 27/100), domain rating (43/100 against 24/100), funding raised ($327M against $40.0M). Degron Therapeutics leads on our overall score (62/100 against 54/100).
What do real users say about Cellares and Degron Therapeutics?
Cellares: 2 positive and 0 negative mentions across 4 Reddit threads we track, mostly in r/CABAinvest.
Read the full Cellares review and pricing or the Degron Therapeutics review and pricing. You can also browse other Cellares alternatives we track.